Literature DB >> 5571307

Kantamaneni BD, Curzon G:Comparison of benefit from L-dopa in Parkinsonism with increase of amine metabolites in the CSF.

R B Godwin-Austen.   

Abstract

Homovanillic acid (HVA) and 5-hydroxy indole acetic acid (5-HIAA) concentrations have been estimated in the cerebrospinal fluid (CSF) of 16 and 18 patients respectively with Parkinsonism both before and during treatment with l-dopa. The rise of HVA correlated with dose of l-dopa. An increase of HVA concentration to less than 0·10 μg/ml. was associated with little or no clinical improvement. The five patients with the greatest increase of HVA concentration/g l-dopa showed little or no improvement from treatment and four of these patients had normal pre-treatment HVA and 5-HIAA. In those patients who responded well to l-dopa the CSF HVA/g l-dopa was intermediate between that of these two groups. It is suggested that change in HVA content of CSF during l-dopa treatment might be of value in the prediction of response to l-dopa.

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 5571307      PMCID: PMC1083454          DOI: 10.1136/jnnp.34.3.219

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  20 in total

1.  [Homovanillic acid in the cerebrospinal fluid: studies in Parkinson's syndrome and other diseases of the CNS].

Authors:  H Bernheimer; W Birkmayer; O Hornykiewicz
Journal:  Wien Klin Wochenschr       Date:  1966-06-10       Impact factor: 1.704

2.  Modification of Parkinsonism--chronic treatment with L-dopa.

Authors:  G C Cotzias; P S Papavasiliou; R Gellene
Journal:  N Engl J Med       Date:  1969-02-13       Impact factor: 91.245

3.  Effects of L-dopa in Parkinson's disease.

Authors:  R B Godwin-Austen; E B Tomlinson; C C Frears; H W Kok
Journal:  Lancet       Date:  1969-07-26       Impact factor: 79.321

4.  Clinical and pharmacological effects of monoamine precursors or haloperidol in chronic schizophrenia.

Authors:  T Persson; B E Roos
Journal:  Nature       Date:  1968-03-02       Impact factor: 49.962

5.  Concentrations of 5-hydroxyindoleacetic acid and homovanillic acid in the cerebrospinal fluid after treatment with probenecid in patients with Parkinson's disease.

Authors:  R Olsson; B E Roos
Journal:  Nature       Date:  1968-08-03       Impact factor: 49.962

6.  Some studies of the effects of chlorpromazine, reserpine and dihydroxyphenylalanine on the concentrations of homovanillic acid, 3,4-dihydroxyphenylacetic acid and 5-hydroxyindol-3-ylacetic acid in ventricular cerebrospinal fluid of the dog using the technique of serial sampling of the cerebrospinal fluid.

Authors:  H C Guldberg; C M Yates
Journal:  Br J Pharmacol Chemother       Date:  1968-07

7.  L-dopa and cerebrospinal fluid homovanillic acid in Parkinsonism.

Authors:  W Weiner; W Harrison; H Klawans
Journal:  Life Sci       Date:  1969-09-01       Impact factor: 5.037

8.  On the occurrence of homovanillic acid and 5-hydroxyindol-3-ylacetic acid in the ventricular C.S.F. of patients suffering from parkinsonism.

Authors:  H C Guldberg; J W Turner; A Hanieh; G W Ashcroft; T B Crawford; W L Perry; F J Gillingham
Journal:  Confin Neurol       Date:  1967

9.  Dopamine formation in brain capillaries--an enzymic blood-brain barrier mechanism.

Authors:  C Owman; E Rosengren
Journal:  J Neurochem       Date:  1967-05       Impact factor: 5.372

10.  5-hydroxyindoleacetic and homovanillic acid levels in the cerebrospinal fluid of healthy volunteers and patients with Parkinson's syndrome.

Authors:  B Johansson; B E Roos
Journal:  Life Sci       Date:  1967-07-01       Impact factor: 5.037

View more
  12 in total

1.  Cognitive enhancement in Korsakoff's psychosis by clonidine: a comparison with L-dopa and ephedrine.

Authors:  R G Mair; W J McEntee
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

Review 2.  Levodopa: a review of its pharmacological properties and therapeutic use with particular reference to Parkinsonism.

Authors:  R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1971       Impact factor: 9.546

3.  [Influence of L-DOPA on night sleep in parkinsonian patients].

Authors:  K Kendel; U Beck; C Wita; E Hohneck; H Zimmermann
Journal:  Arch Psychiatr Nervenkr (1970)       Date:  1972

4.  Certain prediction on the effectiveness of L-DOPA on parkinsonism.

Authors:  S Lavy; O Abramsky; A Carmon; I Yaar; S Feldman
Journal:  Z Neurol       Date:  1973-02-26

Review 5.  Clinical pharmacokinetics of anti-parkinsonian drugs.

Authors:  J M Cedarbaum
Journal:  Clin Pharmacokinet       Date:  1987-09       Impact factor: 6.447

Review 6.  Clinical pharmacokinetics of levodopa in parkinson's disease.

Authors:  J R Bianchine; G M Shaw
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

7.  Failure of cerebrospinal fluid homovanillic acid to predict levodopa response in Parkinson's disease.

Authors:  W J Weiner; H L Klawans
Journal:  J Neurol Neurosurg Psychiatry       Date:  1973-10       Impact factor: 10.154

8.  CSF studies on the relationship between dopamine and 5-hydroxytryptamine in Parkinsonism and other movement disorders.

Authors:  D L Davidson; C M Yates; C Mawdsley; I A Pullar; H Wilson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1977-12       Impact factor: 10.154

9.  Idiopathic orthostatic hypotension treated with levodopa and MAO inhibitor: a preliminary report.

Authors:  J Sharpe; A Marquez-Julio; P Ashby
Journal:  Can Med Assoc J       Date:  1972-08-19       Impact factor: 8.262

10.  Amine metabolites in the cerebrospinal fluid of patients with disseminated sclerosis.

Authors:  L E Claveria; G Curzon; M J Harrison; B D Kantamaneni
Journal:  J Neurol Neurosurg Psychiatry       Date:  1974-06       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.